{"id":2417,"date":"2026-03-12T12:20:00","date_gmt":"2026-03-12T19:20:00","guid":{"rendered":"https:\/\/puny-toaster.flywheelstaging.com\/?p=2417"},"modified":"2026-09-19T20:31:28","modified_gmt":"2026-09-20T03:31:28","slug":"avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device","status":"publish","type":"post","link":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/","title":{"rendered":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device"},"content":{"rendered":"<p>Avisi Technologies, Inc.\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/press-releases\/avisi-technologies-announces-usd10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/\">announced it has secured<\/a>\u00a0$10.7 million in a recent Series A financing round to support the SAPPHIRE pivotal clinical trial evaluating its novel glaucoma treatment device: the VisiPlate.<\/p>\n<p><strong>Where to begin with this?<\/strong><\/p>\n<p>For a quick refresh on Avisi,\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-04-08\/avisi-reports-positive-6-month-data-on-visiplate-aqueous-shunt-for-glaucoma\/#:~:text=First%2C%20tell%20me,disease%20target%3A%20glaucoma.\">click here<\/a>.<\/p>\n<ul>\n<li><em>As for the focus of this coverage:\u00a0<\/em>We\u2019ll start with the\u00a0<strong>VisiPlate<\/strong>\u2014its flagship minimally-invasive bleb surgery (MIBS) device.<\/li>\n<\/ul>\n<p><em>Its purpose:<\/em>\u00a0The device, made from non-fibrotic, nanotechnology-enabled technology, is designed to lower intraocular pressure (IOP).<\/p>\n<p><em>How:<\/em>\u00a0Via a microchannel network that controls aqueous drainage from the anterior surface and minimizes the risk for blockage.<\/p>\n<p>A more in-depth rundown on the VisiPlate can be found\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-10-16\/fda-grants-ide-approval-for-avisi-s-glaucoma-treatment-device\/#:~:text=The%20device%20is,a%20better%20bleb.%E2%80%9D\">here<\/a>.<\/p>\n<p><strong>I\u2019m having trouble picturing this \u2026<\/strong><\/p>\n<p><a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-04-08\/avisi-reports-positive-6-month-data-on-visiplate-aqueous-shunt-for-glaucoma\/#:~:text=For%20a%20look%20at%20this%20in%20action%2C%20see%20below.\">See here<\/a>\u00a0for a visual of the ultrathin shunt\u2019s entire implantation process into the subconjunctival space via an externo procedure with mitomycin C.<\/p>\n<p><strong>Got it. So tell me about the Series A financing.<\/strong><\/p>\n<p>Led by MedVenture Partners\u2014and\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/press-releases\/avisi-technologies-announces-usd10-7m-capital-raise-to-advance-novel-glaucoma-device-development\/#:~:text=The%20Series%20A%20round%20was%20led%20by%20MedVenture%20Partners%2C%20with%20participation%20from%20new%20investors%20Sherpa%20Healthcare%20Partners%2C%20SNBL%2DGemseki%2C%20SBI%20US%20Gateway%20Fund%2C%20Golden%20Seeds%2C%20and%20OneOneFive.\">included participation<\/a>\u00a0from a few new and existing investors\u2014this latest financing round will support Avisi\u2019s pivotal SAPPHIRE clinical trial.<\/p>\n<ul>\n<li>And in case this sounds familiar \u2026 it&#8217;s likely because the FDA\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-10-16\/fda-grants-ide-approval-for-avisi-s-glaucoma-treatment-device\/\">granted investigational device exemption (IDE) approval<\/a>\u00a0for SAPPHIRE just a few months ago.<\/li>\n<\/ul>\n<p><em>Additionally:<\/em>\u00a0The financing is also intended to promote \u201cfurther development\u201d of the company\u2019s pipeline, which includes \u201cnovel treatments addressing the entire spectrum of glaucomatous disease.\u201d<\/p>\n<p><strong>Circle back to that trial \u2026<\/strong><\/p>\n<p>Based in the U.S., SAPPHIRE is a prospective, multicenter, open-label clinical trial (<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876\">NCT07220876<\/a>) evaluating the safety and effectiveness of the VisiPlate in glaucoma patients.<\/p>\n<p>Here\u2019s what we know about\u00a0<strong>these participants:\u00a0<\/strong>An estimated 165 (aged 45+) will be enrolled based on five key inclusion\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876#participation-criteria:~:text=Inclusion%20Criteria%3A,2%20in%20the%20target%20quadrant\">criteria<\/a>:<\/p>\n<ul>\n<li>Open-angle, pseudoexfoliative or pigmentary glaucoma<\/li>\n<li>IOP at pre-op visit of \u2265 20mmHg and \u2264 40mmHg<\/li>\n<li>Visual field mean deviation score of -3dB or worse<\/li>\n<li>Area of healthy, free-and-mobile conjunctiva in the target quadrant<\/li>\n<li>Shaffer angle grade \u2265 in the target quadrant<\/li>\n<\/ul>\n<p><a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876#participation-criteria:~:text=the%20target%20quadrant-,Exclusion%20Criteria%3A,-Angle%20closure%20glaucoma\">See here<\/a>\u00a0for exclusion criteria<\/p>\n<p><strong>And the outcome measures?<\/strong><\/p>\n<p>Both outcome measures will be calculated at 12 months:<\/p>\n<p><strong>The\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876#study-plan:~:text=Primary%20Outcome%20Measures\">primary<\/a>:<\/strong>\u00a0Number of patients (eyes) achieving a \u2265 20% reduction in mean diurnal IOP at 12 months.<\/p>\n<p><strong>The\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876#study-plan:~:text=Secondary%20Outcome%20Measures\">secondary<\/a>:\u00a0<\/strong>Percentage change in mean diurnal IOP, as determined by how much the average eye pressure increased or decreased during the day.<\/p>\n<p><strong>Do we have an official start and end date?<\/strong><\/p>\n<p>Per\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT07220876#study-plan:~:text=CP0005-,Study%20Start%20(Actual),2027%2D10,-Enrollment%20(Estimated\">Clinical Trials<\/a>, the study was initiated in\u00a0<strong>November 2025<\/strong>\u00a0and is estimated to conclude in\u00a0<strong>October 2027<\/strong>.<\/p>\n<p><strong>So \u2026 safe to say it\u2019s ongoing then?<\/strong><\/p>\n<p>Indeed. In fact, Avisi shared that it\u2019s currently enrolling patients from clinic sites in eight states across the country.\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/#:~:text=for%20more%20information.-,Enrolling%20Locations,-Arizona%20Locations%0AGlendale\">See here<\/a>\u00a0for the full list of 16 locations.<\/p>\n<p><strong>While we wait for a data readout, has the VisiPlate undergone any other clinical trial?<\/strong><\/p>\n<p>Yes it has! As we\u00a0<a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-04-08\/avisi-reports-positive-6-month-data-on-visiplate-aqueous-shunt-for-glaucoma\/\">reported in April 2025<\/a>, positive 6-month data from a pilot study on the MIBS device was found to lower open-angle glaucoma (OAG) patients\u2019 mean IOP by 40%.<\/p>\n<p><a class=\"text-primary text-decoration-underline\" href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-04-08\/avisi-reports-positive-6-month-data-on-visiplate-aqueous-shunt-for-glaucoma\/\">Check out our coverage<\/a>\u00a0for the full data recap.<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/glance.eyesoneyecare.com\/stories\/2025-10-16\/fda-grants-ide-approval-for-avisi-s-glaucoma-treatment-device\/?utm_medium=eoe:infinite-scroll\">Read More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Media Contact:<\/strong><br \/>\nSeth Harrington<br \/>\ninfo@avisitech.com<\/p>\n<p>More information on the\u00a0<a role=\"link\" href=\"https:\/\/avisitech.com\/clinical-trials-at-avisi-technologies\/\">SAPPHIRE<\/a>\u00a0clinical trial<\/p>\n<p><strong>SOURCE:<\/strong>\u00a0Avisi Technologies, Inc.<\/p>\n<p><a href=\"https:\/\/eyesoneyecare.com\/?utm_term=eyes%20on%20eyecare&amp;utm_campaign=Branded+-+Keywords&amp;utm_source=adwords&amp;utm_medium=ppc&amp;hsa_tgt=kwd-1170144306890&amp;hsa_grp=123194866451&amp;hsa_src=g&amp;hsa_net=adwords&amp;hsa_mt=b&amp;hsa_ver=3&amp;hsa_ad=497223683226&amp;hsa_acc=7244650218&amp;hsa_kw=eyes%20on%20eyecare&amp;hsa_cam=6945981275&amp;gad_source=1&amp;gad_campaignid=6945981275&amp;gbraid=0AAAAADjCahUmk-sELI0AhUL-5s1nYcJOZ&amp;gclid=CjwKCAjwpcTNBhA5EiwAdO1S9mEcykkth0NYtufsjMcfgvk3X7_AWG7h8tEW3ADNyoGJiwG0P2RorhoCHOoQAvD_BwE\">Eyes on Eyecare<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avisi Technologies, Inc.\u00a0announced it has secured\u00a0$10.7 million in a recent Series A financing round to suppor [&hellip;]<\/p>\n","protected":false},"author":486,"featured_media":2131,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[150],"tags":[],"class_list":["post-2417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.\" \/>\n<meta property=\"og:description\" content=\"Avisi Technologies, Inc.\u00a0announced it has secured\u00a0$10.7 million in a recent Series A financing round to suppor [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/\" \/>\n<meta property=\"og:site_name\" content=\"Avisi Technologies Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T19:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T03:31:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1257\" \/>\n\t<meta property=\"og:image:height\" content=\"839\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ivankornienko\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ivankornienko\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/\"},\"author\":{\"name\":\"ivankornienko\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\"},\"headline\":\"Avisi raises $10.7M to advance study on VisiPlate glaucoma device\",\"datePublished\":\"2026-03-12T19:20:00+00:00\",\"dateModified\":\"2026-09-20T03:31:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/\"},\"wordCount\":520,\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/5.webp\",\"articleSection\":[\"News\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/\",\"name\":\"Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/5.webp\",\"datePublished\":\"2026-03-12T19:20:00+00:00\",\"dateModified\":\"2026-09-20T03:31:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#primaryimage\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/5.webp\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/5.webp\",\"width\":1257,\"height\":839,\"caption\":\"Avisi raises $10.7M to advance study on VisiPlate glaucoma device\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avisi raises $10.7M to advance study on VisiPlate glaucoma device\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#website\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"name\":\"Avisi Technologies Inc.\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#organization\",\"name\":\"Avisi Technologies Inc.\",\"url\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"contentUrl\":\"https:\\\/\\\/avisitech.com\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Avisi-Technologies-Logo-SVG-Final-1.svg\",\"width\":124,\"height\":43,\"caption\":\"Avisi Technologies Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/avisitech.com\\\/ja\\\/#\\\/schema\\\/person\\\/8912f5bbc34efc0fee96277c64d105a5\",\"name\":\"ivankornienko\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g\",\"caption\":\"ivankornienko\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/","og_locale":"ja_JP","og_type":"article","og_title":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.","og_description":"Avisi Technologies, Inc.\u00a0announced it has secured\u00a0$10.7 million in a recent Series A financing round to suppor [&hellip;]","og_url":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/","og_site_name":"Avisi Technologies Inc.","article_published_time":"2026-03-12T19:20:00+00:00","article_modified_time":"2026-09-20T03:31:28+00:00","og_image":[{"width":1257,"height":839,"url":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp","type":"image\/webp"}],"author":"ivankornienko","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ivankornienko","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#article","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/"},"author":{"name":"ivankornienko","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5"},"headline":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device","datePublished":"2026-03-12T19:20:00+00:00","dateModified":"2026-09-20T03:31:28+00:00","mainEntityOfPage":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/"},"wordCount":520,"publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"image":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp","articleSection":["News"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/","url":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/","name":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device - Avisi Technologies Inc.","isPartOf":{"@id":"https:\/\/avisitech.com\/ja\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#primaryimage"},"image":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#primaryimage"},"thumbnailUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp","datePublished":"2026-03-12T19:20:00+00:00","dateModified":"2026-09-20T03:31:28+00:00","breadcrumb":{"@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#primaryimage","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2026\/03\/5.webp","width":1257,"height":839,"caption":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device"},{"@type":"BreadcrumbList","@id":"https:\/\/avisitech.com\/ja\/avisi-raises-10-7m-to-advance-study-on-visiplate-glaucoma-device\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/avisitech.com\/ja\/"},{"@type":"ListItem","position":2,"name":"Avisi raises $10.7M to advance study on VisiPlate glaucoma device"}]},{"@type":"WebSite","@id":"https:\/\/avisitech.com\/ja\/#website","url":"https:\/\/avisitech.com\/ja\/","name":"Avisi Technologies Inc.","description":"","publisher":{"@id":"https:\/\/avisitech.com\/ja\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avisitech.com\/ja\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/avisitech.com\/ja\/#organization","name":"Avisi Technologies Inc.","url":"https:\/\/avisitech.com\/ja\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/","url":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","contentUrl":"https:\/\/avisitech.com\/wp-content\/uploads\/2024\/01\/Avisi-Technologies-Logo-SVG-Final-1.svg","width":124,"height":43,"caption":"Avisi Technologies Inc."},"image":{"@id":"https:\/\/avisitech.com\/ja\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/avisitech.com\/ja\/#\/schema\/person\/8912f5bbc34efc0fee96277c64d105a5","name":"ivankornienko","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/302018db4e1d52c0124450ceca39d595309c13b7907918bd1357932b410ecc81?s=96&d=mm&r=g","caption":"ivankornienko"}}]}},"_links":{"self":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/users\/486"}],"replies":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/comments?post=2417"}],"version-history":[{"count":1,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2417\/revisions"}],"predecessor-version":[{"id":2420,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/posts\/2417\/revisions\/2420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media\/2131"}],"wp:attachment":[{"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/media?parent=2417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/categories?post=2417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avisitech.com\/ja\/wp-json\/wp\/v2\/tags?post=2417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}